This trial tests if ATX01 can help relieve chemotherapy-induced nerve pain in cancer survivors.
- Chemotherapy-induced Peripheral Neuropathy
1 Primary · 11 Secondary · Reporting Duration: 4 weeks, 8 weeks, 12 weeks
3 Treatment Groups
1 of 3
1 of 3
1 of 3
240 Total Participants · 3 Treatment Groups
Primary Treatment: ATX01 15% · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has ATX01 achieved regulatory authorization at the level of 10%?
"ATX01 10% was awarded a safety score of 2 on our internal scale due to the lack clinical data in Phase 2 trials that supports its efficacy." - Anonymous Online Contributor
Are individuals still being accepted to participate in this research?
"Affirmative. Clinicaltrials.gov states that this medical trial is currently accepting participants, with a first post date of January 1st 2023 and most recent update happening on 23rd Jan 2023. The study aims to enrol 240 people at 2 separate locations" - Anonymous Online Contributor
What is the current enrollment capacity of this clinical research trial?
"Affirmative, the clinical trial is currently seeking participants. Initially advertised on January 1st 2023 and most recently updated on January 23rd 2023, this study requires 240 enrollees from two separate locations." - Anonymous Online Contributor